Sprouty 4 Inhibitors
Sprouty 4 (SPRY4) inhibitors represent a collection of chemicals that intricately modulate the activity of SPRY4, shedding light on the molecular mechanisms governing cellular processes related to growth and differentiation. These inhibitors target key components of the RAF/MEK/ERK signaling pathway, which plays a pivotal role in SPRY4 activation. Sorafenib, a multikinase inhibitor, disrupts this pathway, indirectly inhibiting SPRY4 by preventing its activation within a negative feedback loop. Selective MEK inhibitors, including U0126, PD0325901, Selumetinib, Trametinib, PD98059, CI-1040, and AZD6244, offer a specific approach to modulate SPRY4 activity. By targeting MEK, these inhibitors interfere with the downstream signaling cascade, resulting in altered SPRY4 activation and subsequent cellular responses. This specificity highlights their utility in unraveling the complex regulation of SPRY4 and its role in controlling cellular processes.
Raf inhibitors, such as LY3009120, GW5074, PLX4032, and GDC-0879, provide an alternative strategy to indirectly inhibit SPRY4. By disrupting the upstream signaling through the RAF/MEK/ERK pathway, these compounds interfere with SPRY4 activation, influencing cellular processes related to growth and differentiation. Collectively, the detailed understanding of these SPRY4 inhibitors offers a nuanced exploration of the intricate interplay between signaling pathways and the regulation of cellular growth. These chemicals serve as valuable tools for researchers seeking to decipher the complexities of SPRY4-mediated modulation in various cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly inhibits Sprouty 4 by disrupting the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway. As a downstream target of PI3K, AKT is involved in various cellular processes, including the regulation of Sprouty 4 expression. Inhibition of PI3K by LY294002 leads to decreased AKT activation, subsequently influencing Sprouty 4 expression and function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, acts as a direct inhibitor of Sprouty 4 by targeting the MAPK pathway. Specifically inhibiting MEK, PD98059 disrupts the MAPK signaling cascade, impacting Sprouty 4 expression and function. As a negative regulator within the MAPK pathway, Sprouty 4 undergoes altered regulation in response to PD98059-induced MEK inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly inhibits Sprouty 4 by disrupting the PI3K/AKT signaling pathway. As a downstream target of PI3K, AKT is involved in various cellular processes, including the regulation of Sprouty 4 expression. Inhibition of PI3K by Wortmannin leads to decreased AKT activation, subsequently influencing Sprouty 4 expression and function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAP kinase inhibitor, acts as an indirect inhibitor of Sprouty 4 by disrupting the p38 MAP kinase signaling pathway. As a downstream target of p38 MAP kinase, Sprouty 4 undergoes modulation in response to SB203580-induced inhibition. This disruption influences cellular processes associated with growth and differentiation, providing insights into the intricate interplay between p38 MAP kinase signaling and Sprouty 4 regulation. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511, a PI3K inhibitor, indirectly inhibits Sprouty 4 by disrupting the PI3K/AKT signaling pathway. As a downstream target of PI3K, AKT is involved in various cellular processes, including the regulation of Sprouty 4 expression. Inhibition of PI3K by LY303511 leads to decreased AKT activation, subsequently influencing Sprouty 4 expression and function. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103, a dual PI3K/mTOR inhibitor, indirectly inhibits Sprouty 4 by disrupting the PI3K/AKT signaling pathway. As a downstream target of PI3K, AKT is involved in various cellular processes, including the regulation of Sprouty 4 expression. Inhibition of PI3K by PI-103 leads to decreased AKT activation, subsequently influencing Sprouty 4 expression and function. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, a MEK inhibitor, acts as a direct inhibitor of Sprouty 4 by targeting the MAPK pathway. Specifically inhibiting MEK, Selumetinib disrupts the MAPK signaling cascade, impacting Sprouty 4 expression and function. As a negative regulator within the MAPK pathway, Sprouty 4 undergoes altered regulation in response to AZD6244-induced MEK inhibition. | ||||||
PI 3-Kγ Inhibitor | 648450-29-7 | sc-203191 | 5 mg | $76.00 | ||
PI 3-Kγ Inhibitor indirectly inhibits Sprouty 4 by disrupting the PI3K/AKT signaling pathway. As a downstream target of PI3K, PI 3-Kγ Inhibitor is involved in various cellular processes, including the regulation of Sprouty 4 expression. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745, a p38 MAP kinase inhibitor, acts as an indirect inhibitor of Sprouty 4 by disrupting the p38 MAP kinase signaling pathway. As a downstream target of p38 MAP kinase, Sprouty 4 undergoes modulation in response to VX-745-induced inhibition. This disruption influences cellular processes associated with growth and differentiation, providing insights into the intricate interplay between p38 MAP kinase signaling and Sprouty 4 regulation. | ||||||